The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo. The gene discussed is HDAC9; the disease is B-cell chronic lymphocytic leukemia.